Why the study?
Does tropisetron prevent high glucose-induced cardiomyocyte hypertrophy in H9c2 myocardial cells?
Does tropisetron prevent high glucose-induced cardiomyocyte hypertrophy in H9c2 myocardial cells?
Tropisetron protects against high glucose-induced cardiomyocyte hypertrophy in vitro by blocking the calcineurin/NFAT signaling pathway.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for tropisetron in diabetic cardiomyopathy; leaves open translation beyond cell models.
OBJECTIVES: Cardiomyocyte hypertrophy is an important structural feature of diabetic cardiomyopathy. Calcineurin/nuclear factor of activated T-cell (NFAT) pathway plays a central role in the pathogenesis of cardiac hypertrophy. The purpose of this study was to investigate the effects of tropisetron, a novel calcineurin inhibitor, on high glucose (HG)-induced cardiomyocyte hypertrophy and its underlying mechanism. METHODS: H9c2 myocardial cells were treated with tropisetron or cyclosporine A 1 h before exposure to HG for 48 h. KEY FINDINGS: Exposure to HG resulted in enhanced cell size, protein content and atrial natriuretic peptide (ANP) protein expression. HG significantly increased Ca(2+) level, calcineurin expression and nuclear translocation of NFATc4. Both tropisetron and cyclosporine A markedly prevented the hypertrophic characteristic features, calcineurin overexpression and nuclear localization of NFATc4 while intracellular Ca(2+) was not affected. CONCLUSION: Our results showed that tropisetron may have protective effects against HG-induced cardiomyocyte hypertrophy. The mechanism responsible for this beneficial effect seems to be, at least in part, blockade of calcineurin/NFAT signalling pathway.
No takes yet. Share an insight, caveat, or question.
Asadi et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: